We are live on ! Find out more
FDMT icon

4D Molecular Therapeutics
FDMT

145 hedge funds and large institutions have $262M invested in 4D Molecular Therapeutics in 2024 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 50 increasing their positions, 46 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

132% more call options, than puts

Call options by funds: $858K | Put options by funds: $370K

19% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 27

4% more funds holding

Funds holding: 140 → 145 (+5)

9% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 46

10.73% less ownership

Funds ownership: 112.06% → 101.33% (-11%)

58% less capital invested

Capital invested by funds: $630M → $262M (-$369M)

Holders
145
Holders Change
+5
Holders Change %
+3.57%
% of All Funds
1.91%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
32
Increased
50
Reduced
46
Closed
27
Calls
$858K
Puts
$370K
Net Calls
+$488K
Net Calls Change
+$33K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$10.5M
2
Goldman Sachs
Goldman Sachs
New York
+$5.37M
3
JP Morgan Chase
JP Morgan Chase
New York
+$3.96M
4
Citadel Advisors
Citadel Advisors
Florida
+$3.75M
5
CSS
Cubist Systematic Strategies
Connecticut
+$3.36M

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$37M
2
DTC
Deep Track Capital
Connecticut
-$27.4M
3
VA
VR Adviser
New York
-$11.4M
4
PCH
Polar Capital Holdings
United Kingdom
-$9.06M
5
State Street
State Street
Massachusetts
-$7.88M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$27.4M +$412K +52,532 +1%
RCM
2
RA Capital Management
Massachusetts
$25.4M -$4.2M -535,000 -10%
Goldman Sachs
3
Goldman Sachs
New York
$23.8M +$5.37M +683,943 +19%
VA
4
VR Adviser
New York
$16.4M -$11.4M -1,447,629 -33%
Vanguard Group
5
Vanguard Group
Pennsylvania
$15.9M +$728K +92,791 +3%
BI
6
BVF Inc
California
$14.9M -$37M -4,712,000 -64%
Janus Henderson Group
7
Janus Henderson Group
United Kingdom
$12.5M -$6.94M -884,847 -28%
Morgan Stanley
8
Morgan Stanley
New York
$10.4M +$1.26M +160,718 +9%
NHAS
9
Novo Holdings A/S
Denmark
$8.36M – – –
Millennium Management
10
Millennium Management
New York
$7.91M +$10.5M +1,337,497 +1,607%
B
11
Braidwell
Connecticut
$6.83M – – –
RG
12
Redmile Group
California
$6.67M -$512K -65,180 -5%
CC
13
Casdin Capital
New York
$6.41M – – –
State Street
14
State Street
Massachusetts
$6.2M -$7.88M -1,003,785 -47%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$5.64M -$191K -24,383 -2%
JP Morgan Chase
16
JP Morgan Chase
New York
$4.57M +$3.96M +504,086 +160%
ACH
17
ArrowMark Colorado Holdings
Colorado
$4.43M -$69.8K -8,892 -1%
Assenagon Asset Management
18
Assenagon Asset Management
Luxembourg
$3.64M -$6.98M -889,884 -58%
DTC
19
Deep Track Capital
Connecticut
$3.4M -$27.4M -3,486,552 -85%
Citadel Advisors
20
Citadel Advisors
Florida
$3.37M +$3.75M +477,444 +374%
Norges Bank
21
Norges Bank
Norway
$2.79M -$187K -23,888 -5%
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
22
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$2.56M – – –
CSS
23
Cubist Systematic Strategies
Connecticut
$2.5M +$3.36M +428,285 +2,085%
Northern Trust
24
Northern Trust
Illinois
$2.45M +$78.3K +9,982 +2%
DC
25
Decheng Capital
California
$2.23M +$17K +2,165 +0.5%
1
2 3 4 5

FDMT Hedge Fund Activity: Q4 2024 in Review

145 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q4 2024, worth a combined $262M — down 58% from $630M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new FDMT positions and 27 closed out — a net gain of 5 holders — while 50 added to existing stakes and 46 trimmed.

The largest buyer was Millennium Management, adding an estimated $10.5M. The largest seller was BVF Inc, cutting an estimated $37M.

  • 145 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q4 2024, up from 140 in Q3 2024.
  • Funds reported $262M of 4D Molecular Therapeutics stock for Q4 2024, down 58% quarter-over-quarter.
  • 32 funds opened new 4D Molecular Therapeutics positions in Q4 2024 and 27 closed out, a net change of +5 holders.
  • The largest 4D Molecular Therapeutics buyer in Q4 2024 was Millennium Management, an estimated $10.5M added.
  • The largest 4D Molecular Therapeutics seller in Q4 2024 was BVF Inc, an estimated $37M sold.

Based on aggregated 13F filings for Q4 2024.